586P Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
Abida, W., Iannotti, N., Kocabas Argon, E., Appleman, L., Michaud, N., Rajarethinam, A., Adib, D., Saltzstein, D.R.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article